Vertex Pharmaceuticals Inc (VRTX)

VRTX (NASDAQ:Drugs) EQUITY
$93.06
pos +2.70
+3.00%
Today's Range: 90.61 - 93.60 | VRTX Avg Daily Volume: 2,113,800
Last Update: 05/31/16 - 4:00 PM EDT
Volume: 1,737,564
YTD Performance: -28.17%
Open: $90.64
Previous Close: $90.38
52 Week Range: $75.90 - $143.45
Oustanding Shares: 247,349,864
Market Cap: 22,355,480,708
6-Month Chart
TheStreet Ratings Grade for VRTX
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 9 9 9 9
Moderate Buy 2 2 2 1
Hold 5 5 5 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.72 1.72 1.72 1.70
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -54.78
Price Earnings Comparisons:
VRTX Sector Avg. S&P 500
-54.78 0.00 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
3.89% -29.28% 15.28%
GROWTH 12 Mo 3 Yr CAGR
Revenue 77.90 -0.30 -0.12
Net Income 0.00 10.50 0.00
EPS 0.00 3.60 0.00
Earnings for VRTX:
EBITDA -0.40B
Revenue 1.03B
Average Earnings Estimates
Qtr (06/16) Qtr (09/16) FY (12/16) FY (12/17)
Average Estimate $0.05 $0.17 $0.44 $2.49
Number of Analysts 4 4 4 3
High Estimate $0.25 $0.42 $1.33 $2.86
Low Estimate $-0.12 $0.02 $-0.07 $2.09
Prior Year $-0.80 $-0.40 $-2.07 $0.44
Growth Rate (Year over Year) 105.63% 141.25% 121.01% 473.18%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
By

Jim Cramer

 | May 9, 2016 | 2:40 PM EDT

The answer is that new data came out.

By

Bruce Kamich

 | Apr 27, 2016 | 8:31 AM EDT

The rate of decline slowed into the base, just what chartists like to see. 

bullishVertex upgraded at Jefferies

Feb 1, 2016 | 7:13 AM EST

VRTX was upgraded from Hold to Buy, Jefferies said. Valuation call, based on a $120 price target.

bullishVertex upgraded at HC Wainwright

Oct 30, 2015 | 7:26 AM EDT

VRTX was upgraded to Buy, HC Wainwright said. $155 price target. Company has a sound strategy and should continue to execute well. 

bullishVertex upgraded at Morgan Stanley

Oct 2, 2015 | 7:58 AM EDT

VRTX was upgraded from Equal-weight to Overweight, Morgan Stanley said. Company is transitioning toward profitability and should outperform. $148 price target. 

bullishVertex upgraded at Barclays

Sep 14, 2015 | 8:10 AM EDT

VRTX was upgraded to Overweight, Barclays said. $150 price target. Expert feedback suggest upside for Orkambi.

By

Jim Cramer

 | Aug 10, 2015 | 5:40 AM EDT

There are some good buying ideas among these stocks.

bearishVertex estimates, target cut at JMP

Jul 6, 2015 | 7:38 AM EDT

Shares of VRTX now seen reaching $145, according to JMP Securities. Estimates also reduced, given lower realized pricing for Orkambi. Outperform rating. 

By

Dan Fitzpatrick

 | May 27, 2015 | 5:00 PM EDT

Sector may not be as bulletproof as we thought.

By

Jim Cramer

 | May 13, 2015 | 11:17 AM EDT

Jim Cramer answers viewers' stock questions from the floor of the New York Stock Exchange.

The Fed has been talkative lately about the 'strength' in the economy with a 2% rate of gr...
Market flat as we hit the noon hour. Oil tries once again to scale the $50 level. Biotec...
I would think he sees the boatload of cash coming to AGN if/when they close the TEVA deal ...
Looking like a slightly up start to the holiday shortened trading week as consumer spendin...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.